Department of Microbiology and Systems Biology, Netherlands Organisation for Applied Scientific Research (TNO), Leiden, The Netherlands.
Gut Microbes. 2024 Jan-Dec;16(1):2402544. doi: 10.1080/19490976.2024.2402544. Epub 2024 Sep 17.
Post-COVID syndrome (PCS) patients have reported a wide range of symptoms, including fatigue, shortness of breath, and diarrhea. Particularly, the presence of gastrointestinal symptoms has led to the hypothesis that the gut microbiome is involved in the development and severity of PCS. The objective of this review is to provide an overview of the role of the gut microbiome in PCS by describing the microbial composition and microbial metabolites in COVID-19 and PCS. Moreover, host-microbe interactions via the microbiota-gut-brain (MGB) and the microbiota-gut-lung (MGL) axes are described. Furthermore, we explore the potential of therapeutically targeting the gut microbiome to support the recovery of PCS by reviewing preclinical model systems and clinical studies. Overall, current studies provide evidence that the gut microbiota is affected in PCS; however, diversity in symptoms and highly individual microbiota compositions suggest the need for personalized medicine. Gut-targeted therapies, including treatments with pre- and probiotics, have the potential to improve the quality of life of affected individuals.
新冠后综合征（PCS）患者报告了一系列症状，包括疲劳、呼吸急促和腹泻。特别是，胃肠道症状的存在导致了这样一种假设，即肠道微生物组参与了 PCS 的发生和严重程度。本综述的目的是通过描述 COVID-19 和 PCS 中的微生物组成和微生物代谢物，概述肠道微生物组在 PCS 中的作用。此外，还通过微生物群-肠-脑（MGB）和微生物群-肠-肺（MGL）轴描述了宿主-微生物相互作用。此外，我们通过综述临床前模型系统和临床研究，探讨了通过靶向肠道微生物组来支持 PCS 恢复的治疗潜力。总的来说，目前的研究提供了证据表明，PCS 中肠道微生物组受到了影响；然而，症状的多样性和高度个体化的微生物组成表明需要个性化治疗。针对肠道的治疗方法，包括使用益生菌和益生元的治疗方法，有可能改善受影响个体的生活质量。
